Strong Site Engagement for ALPHA3 Trial
The ALPHA3 trial has seen significant site engagement, with nearly 50 activated U.S. sites and plans for international expansion. Over 250 patients have consented for MRD screening, with nearly half in the last three months.
Extended Cash Runway
Allogene has extended its cash runway into the second half of 2027, allowing it to navigate market headwinds and continue advancing its trials.
ALLO-316 Shows Promise in Solid Tumors
ALLO-316 continues to show efficacy in patients with advanced renal cell carcinoma, providing hope for heavily pretreated patients. The upcoming oral presentation at ASCO on June 1st is expected to showcase further results.
Advancements in Autoimmune Disease with ALLO-329
ALLO-329 is set to change the treatment of autoimmune diseases with its innovative design that could eliminate lymphodepletion. The RESOLUTION trial is expected to launch mid-2025.